Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company whose news flow centers on its TGF-ß pathway–focused pipeline, corporate strategy and capital allocation decisions. The company’s disclosures describe a focus on developing protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, with particular emphasis on neuromuscular and hematologic conditions.
News about Keros frequently highlights clinical development milestones for its lead product candidate, KER-065, which is being developed for neuromuscular diseases with an initial focus on Duchenne muscular dystrophy. Recent updates have included Phase 1 clinical data in healthy volunteers, additional analyses of bone and muscle-related endpoints, and U.S. Food and Drug Administration Orphan Drug designation for KER-065 in DMD. Investors following KROS news can expect coverage of trial design, safety and pharmacodynamic findings, and plans for subsequent clinical phases.
Another recurring theme in Keros news is progress related to elritercept, the company’s most advanced product candidate for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. The company has reported developments under its global license agreement with Takeda Pharmaceuticals U.S.A., Inc., including Takeda’s plans to advance elritercept into a Phase 3 clinical trial in first-line myelodysplastic syndromes.
Keros’ news flow also includes corporate and financial updates. These have covered a strategic realignment to prioritize KER-065, discontinuation of internal development of cibotercept (KER-012), leadership and board changes, and a substantial capital return program involving stock repurchase agreements and a cash tender offer for a significant portion of its outstanding common stock. Earnings releases and Form 8-K filings provide additional context on financial results, cash position and the execution of the capital return plan.
For investors and observers, the KROS news page offers a consolidated view of clinical trial announcements, regulatory designations, partnership developments, governance changes and capital allocation actions that shape the company’s trajectory. Regular review of these updates can help track how Keros advances its TGF-ß–focused pipeline and manages its resources over time.
Keros Therapeutics (NASDAQ: KROS) presented additional clinical data from its Phase 1 trial of KER-065 at the American Society of Bone and Mineral Research 2025 Annual Meeting. The trial, conducted in healthy male volunteers, demonstrated that KER-065, a modified activin receptor ligand trap, was generally well-tolerated with no serious adverse events related to treatment.
The study showed promising results for bone health, with sustained improvements in bone mineral density (BMD) through Day 141, particularly in whole body and lumbar spine measurements. The data supports KER-065's potential development for treating Duchenne muscular dystrophy and bone disorders, where bone loss occurs due to muscle weakness and corticosteroid use.
Keros Therapeutics (NASDAQ:KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its participation in two upcoming healthcare conferences.
CEO Jasbir S. Seehra will present at the 2025 Wells Fargo Healthcare Conference on September 4 at 2:15 p.m. ET in a fireside chat format, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 9 at 12:00 p.m. ET as a corporate presentation. Replays will be available on the company's investor relations website for 90 days after each event.
ADAR1 Capital Management, Keros Therapeutics' (NASDAQ: KROS) largest shareholder with a 13.3% stake, has issued an open letter to the company's Board expressing frustration over their refusal to engage in discussions about strategy and governance.
The letter criticizes the Board's lack of progress on their June 9 announcement to return $375 million in excess capital to shareholders and urges for a special dividend. ADAR1 believes Keros is significantly undervalued, citing the company's cash balance and the Takeda partnership for elritercept as key value drivers.
ADAR1 threatens to seek new director elections at the next Annual Meeting if the Board continues to refuse engagement, while warning against making strategic changes without major stockholder input.
Keros Therapeutics (Nasdaq: KROS) has received Orphan Drug designation from the FDA for KER-065, its investigational therapy for Duchenne muscular dystrophy (DMD). This milestone comes as the company prepares to advance KER-065 into Phase 2 clinical trials for DMD patients.
The Orphan Drug designation provides significant benefits, including tax credits for clinical testing, potential FDA fee waivers, and seven years of market exclusivity upon approval. This designation is granted to therapies targeting rare diseases affecting fewer than 200,000 people in the United States.
Keros Therapeutics (NASDAQ:KROS) announced a major strategic realignment to focus exclusively on advancing KER-065, their lead clinical program for Duchenne muscular dystrophy (DMD). The company is discontinuing development of cibotercept (KER-012), following its previously terminated Phase 2 TROPOS trial in pulmonary arterial hypertension.
Significant leadership changes include CEO Jasbir S. Seehra, Ph.D. assuming the additional role of President, while stepping down as Board Chair. Jean-Jacques Bienaimé has been appointed as the new Board Chair, and Lorena Lerner, Ph.D. has been promoted to Chief Scientific Officer. The company plans to initiate a Phase 2 clinical trial of KER-065 in DMD patients in Q1 2026, following positive Phase 1 results in healthy volunteers.
Keros Therapeutics (NASDAQ: KROS) reported its Q2 2025 financial results, marking significant developments following a comprehensive strategic review. The company posted a net loss of $30.7 million, an improvement from the $45.3 million loss in Q2 2024. Key financial metrics include R&D expenses of $43.5 million and cash position of $690.2 million.
The company plans to return $375 million to stockholders while maintaining sufficient capital to fund operations into first half of 2028. Keros is advancing its pipeline, particularly KER-065, with plans to initiate a Phase 2 trial for Duchenne muscular dystrophy in Q1 2026. The company's improved financial position was supported by revenue from its license agreement with Takeda Pharmaceuticals.
Keros Therapeutics (Nasdaq: KROS) has announced the first patient dosing in its Phase 3 RENEW clinical trial of elritercept, targeting adults with transfusion-dependent anemia in myelodysplastic syndromes (MDS). This milestone triggered a $10 million payment from Takeda under their global license agreement.
The agreement, effective since January 2025, included a $200 million upfront payment and potential milestone payments exceeding $1.1 billion. Keros maintains rights to receive tiered royalties on net sales, while Takeda holds commercialization rights worldwide except for mainland China, Hong Kong, and Macau.